ストックスクリーナーアプリを入手
29.58
1.83%
-0.55
前日終値:
$30.13
開ける：
$30.2
24時間の取引高:
197.60K
Relative Volume:
0.72
時価総額：
$1.51B
収益：
$345.60M
当期純損益:
$-79.01M
株価収益率:
-18.44
EPS:
-1.6045
ネットキャッシュフロー:
$-18.62M
1週間 パフォーマンス:
-0.77%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-5.80%
1年 パフォーマンス:
-54.49%
1日の値動き範囲:
$29.29
$30.50
1週間の範囲:
$28.92
$30.50
52週間の値動き範囲:
$27.19
$66.00
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
名前
Immunocore Holdings Plc Adr
セクター
電話
01235 5430281
住所
90 PARK DRIVE, OXFORDSHIRE
IMCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
29.58 | 1.51B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-10-24 | 開始されました | UBS | Sell |
| 2024-10-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 開始されました | Needham | Buy |
| 2023-08-16 | 開始されました | CapitalOne | Overweight |
| 2023-07-17 | 開始されました | Canaccord Genuity | Hold |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-03-30 | 開始されました | Guggenheim | Buy |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2022-12-16 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-30 | 開始されました | Barclays | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-08-08 | 開始されました | Cowen | Outperform |
| 2022-08-02 | 開始されました | BTIG Research | Buy |
| 2022-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-20 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | Goldman | Neutral |
| 2021-03-02 | 開始されました | JP Morgan | Overweight |
| 2021-03-02 | 開始されました | Jefferies | Buy |
すべてを表示
Immunocore Holdings Plc Adr (IMCR) 最新ニュース
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com India
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade - Yahoo Finance
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Zacks Investment Research
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer - Yahoo Finance
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
SNTI Stock Skyrockets On Initial Data From Phase I Cancer Study - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - Yahoo Finance
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Immunocore Holdings Plc Adr (IMCR) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):